Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: Comparison with histopathology after salvage lymphadenectomy

Journal of Nuclear Medicine

Volumn 57, Issue 11, 2016, Pages 1713-1719

  Rauscher, Isabel ^a   Maurer, Tobias ^a   Beer, Ambros J ^b   Graner, Frank Philipp ^a   Haller, Bernhard ^a   Weirich, Gregor ^a   Doherty, Alan ^c   Gschwend, Jürgen E ^a   Schwaiger, Markus ^a   Eiber, Matthias ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

68Ga PSMA HBED CC; Computed tomography; Hybrid imaging; Magnetic resonance imaging; Positron emission tomography; Prostate cancer; Salvage lymphadenectomy

Indexed keywords

GALLIUM 68; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER RECURRENCE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; ADULT; AGED; BIOPSY; COMPARATIVE STUDY; DIAGNOSIS; DIAGNOSTIC IMAGING; LYMPH NODE; MALE; MIDDLE AGED; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; PROSTATIC NEOPLASMS; REPRODUCIBILITY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; BIOPSY; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84994875784     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.173492     Document Type: Article

References (36)

1. Freedland SJ, Presti JC Jr, Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736-741.
2. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-523.
3. Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:380-385.
4. Suardi N, Gandaglia G, Gallina A, et al. Long-Term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67:299-309.
5. Abdollah F, Briganti A, Montorsi F, et al. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol. 2015;67:839-849.
6. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-2499.
7. Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-Analysis. Clin Radiol. 2008;63:387-395.
8. Briganti A, Abdollah F, Nini A, et al. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol. 2012;61:1132-1138.
9. Wibmer AG, Burger IA, Sala E, et al. Molecular imaging of prostate cancer. Radiographics. 2016;36:142-159.
10. Scattoni V, Picchio M, Suardi N, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423-429.
11. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [11C]choline- PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23.
12. Fanti S, Minozzi S, Castellucci P, et al. PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016;43:55-69.
13. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
14. Afshar-Oromieh A, Haberkorn U, Hadaschik B, et al. PET/MRI with a 68Ga- PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1629-1630.
15. Roethke MC, Kuru TH, Afshar-Oromieh A, et al. Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: A next step for imaging of recurrent prostate cancer- preliminary results. Eur Urol. 2013;64:862-864.
16. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
17. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42: 197-209.
18. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
19. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436-1443.
20. Eder M, Neels O, Muller M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: A new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014;7:779-796.
21. Souvatzoglou M, Eiber M, Martinez-Moeller A, et al. PET/MR in prostate cancer: Technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging. 2013;40 suppl 1:S79-S88.
22. Obuchowski NA. Nonparametric analysis of clustered ROC curve data. Biometrics. 1997;53:567-578.
23. Smith PJ, Hadgu A. Sensitivity and specificity for correlated observations. Stat Med. 1992;11:1503-1509.
24. Genders TS, Spronk S, Stijnen T, et al. Methods for calculating sensitivity and specificity of clustered data: A tutorial. Radiology. 2012;265:910-916.
25. Hijazi S, Meller B, Leitsmann C, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015;75:1934-1940.
26. Herlemann A, Wenter V, Kretschmer A, et al. Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. January 19, 2016 [Epub ahead of print].
27. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of [11C]-choline positronemission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786-793.
28. Tilki D, Reich O, Graser A, et al. 18F-fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol. 2013;63:792-796.
29. Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane antigenradioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68:530-534.
30. Freitag MT, Radtke JP, Hadaschik BA, et al. Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:70-83.
31. Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI perform equally well in cancer: Evidence from studies on more than 2, 300 patients. J Nucl Med. 2016;57:420-430.
32. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-855.
33. Gaertner FC, Beer AJ, Souvatzoglou M, et al. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors. Invest Radiol. 2013;48:263-272.
34. Souvatzoglou M, Eiber M, Takei T, et al. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1486-1499.
35. Giesel FL, Fiedler H, Stefanova M, et al. PSMA PET/CT with Glu-urea-Lys- (Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1794-1800.
36. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887-897.